Fursultiamine

Fursultiamine belongs to the allithiamine family of thiamine derivatives, a group of compounds in which the thiazole ring of vitamin B1 has been opened to expose a reactive thiol that is then joined to another group through a disulfide bond ^[1]. In fursultiamine that partner group is a tetrahydrofurfuryl moiety, which gives the molecule its alternative name, thiamine tetrahydrofurfuryl disulfide, or TTFD ^[1]. The design goal was to keep the vitamin activity of thiamine while making the molecule far more lipid-soluble, so that it can pass through cell membranes more easily than the charged, water-soluble vitamin ^[2].

The story begins with allithiamine, a naturally occurring disulfide form of thiamine that Japanese researchers isolated from garlic and other Allium plants in 1951 ^[1]. Investigators working with the Vitamin B Research Committee of Japan found that this garlic-derived form carried thiamine into tissues more effectively than the ordinary vitamin, and they went on to synthesize a series of related disulfide derivatives ^[1]. Fursultiamine, developed in the 1960s, is one of the best known of these synthetic analogues and was later marketed in Japan, parts of Europe, and elsewhere ^[1].

Its main established use is the treatment and prevention of thiamine deficiency, including the classic deficiency disease beriberi ^[1]. Because the brain is highly sensitive to a shortage of thiamine, lipid-soluble derivatives such as fursultiamine and the closely related sulbutiamine have attracted interest for raising thiamine levels in nervous tissue, in contrast to benfotiamine, an S-acyl derivative that boosts thiamine in blood and liver but not in the brain ^[2]. Laboratory work also indicates that these disulfide derivatives interact with the cell's thiol redox systems and can switch on antioxidant defenses, which may contribute to effects beyond simple vitamin replacement ^[3].

Fursultiamine is regulated as a vitamin medicine rather than a controlled substance and is generally available without prescription; it has been sold under brand names such as Alinamin-F and Lipothiamine, among others ^[1]. It is supplied mainly as oral tablets and capsules, sometimes combined with other B vitamins ^[1].

TOLERABILITY: Generally well tolerated at vitamin-replacement doses. The 12-week Alzheimer's trial at 100 mg/day reported no adverse reactions and full tolerance (PMID 8815393). A 6-week mouse study up to 500 mg/kg/day found no adverse signal on body composition, blood biochemistry or histopathology (PMID 29966293), though that study was co-authored by a pharmaceutical manufacturer.

DOCUMENTED ADVERSE EFFECTS: - Gastrointestinal irritation. Explicitly flagged by investigators as a risk requiring management in paediatric TTFD therapy (PMID 21816221). - Refeeding syndrome from the infusion vehicle. High-dose parenteral fursultiamine carries glucose; its caloric contribution was overlooked and precipitated refeeding syndrome during Wernicke encephalopathy treatment (PMID 42476772). Count the vehicle calories. - Secondary pulmonary oedema after rapid thiamine repletion in a severely deficient patient (PMID 31534090). This is a haemodynamic consequence of correcting deficiency rather than direct drug toxicity, but it is a real risk of treating advanced beriberi. - Behavioural effects in juvenile mice at 100 and 340 mg/kg/day: reduced activity, altered social interaction, decreased acoustic startle and lower percentage weight gain (PMID 21816221). Relevant because these are the doses used in the paediatric supplementation literature by allometry. - Sulfurous garlic-like breath and body odour is widely reported by users and is chemically plausible from the disulfide, but no controlled incidence figure was found in the peer-reviewed literature.

INTERACTIONS: No published human drug-interaction study was found. Two theoretical concerns follow from the chemistry rather than from data: the thiol-reactive behaviour at ferroportin C326 (PMID 23292796) means iron handling is a plausible interaction surface, and the compound is a substrate for thioredoxin reductase and glutathione (PMID 39302148), so it consumes reducing equivalents. Neither has been tested in people. Fursultiamine had no effect on plasma CGRP, VIP, motilin or substance P in healthy volunteers, unlike pantethine (PMID 21963510).

REGULATORY STATUS: - JAPAN: approved prescription and OTC medicine since 1 May 1961 (Takeda, Alinamin-F). Also widely marketed in South Korea and parts of Asia. - UNITED STATES: NOT FDA approved. The single DailyMed listing containing fursultiamine (ARONAMIN GOLD, 50 mg, human OTC) carries marketing category "unapproved drug other" and the statutory disclaimer that the drug has not been found by FDA to be safe and effective; its NDC was inactivated by FDA-initiated compliance action. It is not a scheduled substance. It is sold in the US as a supplement ingredient. - WADA: not on the 2026 Prohibited List. No vitamin B1 derivative appears in any prohibited class, and the 2026 modifications do not mention thiamine. This is a reasoned negative from the list text rather than a direct GlobalDRO query, which could not be executed; athletes should verify on GlobalDRO because the list is revised annually. - PREGNANCY AND LACTATION: no adequate published human safety data specific to fursultiamine.